MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Search

Ionis Pharmaceuticals Inc

Cerrado

SectorSalud

81.41 1.71

Resumen

Variación precio

24h

Actual

Mínimo

78.76

Máximo

82.04

Métricas clave

By Trading Economics

Ingresos

-252M

-129M

Ventas

-295M

157M

Margen de beneficio

-82.062

Empleados

1,069

EBITDA

-245M

-94M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+13.65% upside

Dividendos

By Dow Jones

Próximas Ganancias

18 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.1B

13B

Apertura anterior

79.7

Cierre anterior

81.41

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

158 / 370 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Ionis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

10 ene 2026, 00:16 UTC

Adquisiciones, fusiones, absorciones

Edwards Lifesciences Drops Merger With JenaValve

11 ene 2026, 23:46 UTC

Charlas de Mercado

Gold Rises Amid Geopolitical Risks -- Market Talk

11 ene 2026, 23:35 UTC

Charlas de Mercado

Oil Rises Amid Middle East Tensions -- Market Talk

11 ene 2026, 23:25 UTC

Ganancias

Stock Futures Drift Lower With Bank Earnings, CPI on Tap -- Barrons.com

11 ene 2026, 22:05 UTC

Charlas de Mercado

Iron Ore Outlook Weighed by Soft China Steel Markets, Rising Supply -- Market Talk

10 ene 2026, 12:00 UTC

Adquisiciones, fusiones, absorciones

Copper Is the Prize in Mining Megadeals -- WSJ

10 ene 2026, 09:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

10 ene 2026, 09:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

10 ene 2026, 09:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 ene 2026, 22:18 UTC

Charlas de Mercado

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 ene 2026, 21:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

9 ene 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

9 ene 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 ene 2026, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

9 ene 2026, 21:43 UTC

Ganancias
Adquisiciones, fusiones, absorciones

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 ene 2026, 20:39 UTC

Charlas de Mercado

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 ene 2026, 20:38 UTC

Charlas de Mercado

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 ene 2026, 20:36 UTC

Adquisiciones, fusiones, absorciones

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 ene 2026, 20:30 UTC

Charlas de Mercado

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 ene 2026, 20:15 UTC

Charlas de Mercado

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 ene 2026, 20:07 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

9 ene 2026, 20:07 UTC

Charlas de Mercado

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 ene 2026, 19:58 UTC

Adquisiciones, fusiones, absorciones

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 ene 2026, 19:42 UTC

Charlas de Mercado

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 ene 2026, 19:38 UTC

Adquisiciones, fusiones, absorciones

Wolters Kluwer Acquires StandardFusion >WTKWY

9 ene 2026, 19:31 UTC

Ganancias

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 ene 2026, 19:28 UTC

Ganancias

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 ene 2026, 18:30 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 ene 2026, 18:23 UTC

Charlas de Mercado

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 ene 2026, 17:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

13.65% repunte

Estimación a 12 meses

Media 92.67 USD  13.65%

Máximo 110 USD

Mínimo 65 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

13

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

29.78 / 33.645Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

158 / 370 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat